Learn who may benefit from cancer immunotherapy, which tests are needed before treatment, including PD-L1, MSI, TMB and NGS, and how RecMed Medical Travel helps international patients access advanced oncology care in Turkey.

 

Keywords:

immunotherapy for cancer, cancer immunotherapy treatment, immunotherapy in Turkey, PD-L1 testing, MSI testing, TMB testing, NGS cancer test, advanced cancer treatment abroad, oncology treatment in Turkey

 

 

 

Immunotherapy for Cancer in Turkey: Who Is Eligible, Which Tests Are Needed, and How Treatment Is Planned

 

Cancer treatment has changed significantly over the last decade. For many patients, especially those with advanced or metastatic cancer, treatment is no longer limited only to surgery, chemotherapy, and radiation therapy. Today, immunotherapy has become one of the most important treatment approaches in modern oncology.

 

However, immunotherapy is not suitable for every cancer patient. The most important question is not only “Can immunotherapy treat cancer?” but rather: “Is this patient truly a candidate for immunotherapy?”

 

To answer this correctly, oncologists often need detailed pathology review, biomarker testing, molecular profiling, and a personalized treatment strategy. At RecMed Medical Travel, we help international patients access advanced oncology evaluation, biomarker testing, second opinions, treatment planning, and hospital coordination in Turkey. RecMed’s official service model focuses on direct access to specialist doctors, accommodation support, transfer services, translators, and post-treatment coordination for international patients.  

 

 

 

What Is Cancer Immunotherapy?

 

Immunotherapy is a type of cancer treatment that helps the patient’s own immune system recognize, attack, and control cancer cells. Normally, the immune system can detect abnormal cells, but cancer can develop mechanisms to hide from immune attack. Some immunotherapy drugs are designed to remove these “brakes” from the immune system so immune cells can attack the tumor more effectively.

 

One of the most widely used groups of immunotherapy drugs is called immune checkpoint inhibitors. These drugs target checkpoint proteins such as PD-1, PD-L1, and CTLA-4. The U.S. National Cancer Institute explains that checkpoint inhibitors block checkpoint proteins from sending an “off” signal to immune cells, allowing T cells to recognize and kill cancer cells more effectively.  

 

Immunotherapy can include several treatment categories, such as:

 

* Immune checkpoint inhibitors

* CAR-T cell therapy

* Monoclonal antibodies

* Bispecific antibodies

* Cancer vaccines

* Oncolytic virus therapy

* Tumor-infiltrating lymphocyte therapy in selected settings

* Other immune-based experimental or clinical trial therapies

 

For most solid tumors, immune checkpoint inhibitors are the most commonly discussed form of immunotherapy. For certain blood cancers, cellular therapies such as CAR-T therapy may also be relevant.

 

 

 

Which Cancer Types May Be Treated With Immunotherapy?

 

Immunotherapy may be used in several cancer types, depending on the tumor stage, molecular profile, previous treatments, and approved treatment indications in the country where care is provided.

 

Cancer types where immunotherapy is commonly considered include:

 

* Non-small cell lung cancer

* Melanoma

* Kidney cancer

* Bladder cancer

* Head and neck cancer

* Liver cancer

* Gastric and gastroesophageal cancer

* Esophageal cancer

* Cervical cancer

* Endometrial cancer

* Triple-negative breast cancer in selected cases

* MSI-H or dMMR colorectal cancer

* Hodgkin lymphoma

* Certain B-cell lymphomas

* Multiple myeloma in selected advanced treatment settings

 

The most important point is that immunotherapy decisions should be individualized. The same diagnosis does not always mean the same treatment. For example, two patients with lung cancer may have completely different treatment strategies depending on PD-L1 level, EGFR mutation status, ALK status, disease stage, previous treatment history, and overall condition.

 

 

 

Why Immunotherapy Does Not Work for Every Patient

 

One of the biggest misunderstandings among patients is the belief that immunotherapy is automatically stronger or better than chemotherapy. In reality, immunotherapy can be highly effective for selected patients, but it may be ineffective or even inappropriate in others.

 

Several factors influence whether immunotherapy may help:

 

* Cancer type

* Disease stage

* PD-L1 expression level

* MSI-H or dMMR status

* Tumor mutational burden

* NGS tumor profile

* Previous chemotherapy, targeted therapy, or radiation

* Presence of autoimmune disease

* Liver, kidney, lung, thyroid, and endocrine function

* General performance status

* Speed of cancer progression

* Tumor burden and metastatic sites

 

This is why modern oncology increasingly uses biomarker-guided treatment selection. Biomarkers such as PD-L1, MSI-H/dMMR, and TMB are widely used in immunotherapy decision-making, but they are not interchangeable and must be interpreted within the full clinical context.  

 

 

 

Essential Tests Before Immunotherapy

 

Before starting immunotherapy, patients usually need a complete oncology evaluation. This often includes pathology review, imaging review, blood tests, and biomarker testing. In many cases, molecular testing can determine whether immunotherapy is likely to be beneficial or whether another treatment may be more appropriate.

 

1. PD-L1 Testing

 

PD-L1 is one of the most important biomarkers used before immune checkpoint inhibitor therapy. Some tumors express PD-L1 to suppress immune attack. Drugs that target PD-1 or PD-L1 may help restore immune activity against cancer cells.

 

PD-L1 testing is especially important in several cancers, including:

 

* Lung cancer

* Gastric cancer

* Triple-negative breast cancer

* Head and neck cancer

* Cervical cancer

* Urothelial cancer

* Esophageal and gastroesophageal cancers

 

However, PD-L1 is not a perfect biomarker. A high PD-L1 result may increase the chance of response in some cancers, but it does not guarantee success. A low or negative PD-L1 result also does not always mean immunotherapy is impossible, because some cancers may respond based on other markers such as MSI-H/dMMR or TMB.

 

2. MSI-H / dMMR Testing

 

MSI-H, meaning microsatellite instability-high, and dMMR, meaning mismatch repair deficiency, are powerful biomarkers in several cancers. Tumors with MSI-H or dMMR often have many abnormal proteins that make them more visible to the immune system.

 

This marker is especially important in:

 

* Colorectal cancer

* Endometrial cancer

* Gastric cancer

* Small bowel cancer

* Pancreatic cancer in selected cases

* Other advanced solid tumors

 

The FDA’s first tissue-agnostic cancer drug approval was for pembrolizumab in adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that progressed after prior treatment and had no satisfactory alternative treatment options. This was a major milestone because the treatment indication was based on a biomarker rather than the organ where the cancer started.  

 

3. Tumor Mutational Burden Testing

 

Tumor Mutational Burden, commonly called TMB, measures how many mutations are present in a tumor. Some tumors with a high number of mutations may produce more abnormal proteins, making them more recognizable to the immune system.

 

In 2020, the FDA granted accelerated approval to pembrolizumab for adult and pediatric patients with unresectable or metastatic TMB-high solid tumors, defined as at least 10 mutations per megabase, after progression on prior treatment and when no satisfactory alternative treatment options exist.  

 

TMB must be interpreted carefully. It is not equally predictive in all cancer types, and results may vary depending on the testing platform. For this reason, TMB should be evaluated together with the patient’s diagnosis, pathology, previous treatments, imaging findings, and other biomarkers.

 

4. NGS Tumor Profiling

 

Next-Generation Sequencing, or NGS, is a comprehensive molecular test that analyzes cancer-related genes and sometimes broader genomic signatures. NGS can help identify:

 

* Targetable mutations

* Resistance mutations

* MSI status

* TMB level

* HER2 alterations

* BRCA1/BRCA2 mutations

* NTRK fusions

* RET, MET, ALK, ROS1, BRAF, EGFR and other actionable changes

* Potential clinical trial options

 

For many advanced cancer patients, NGS is extremely valuable because it can show whether the patient may benefit from targeted therapy, immunotherapy, clinical trials, or a different treatment sequence.

 

In my opinion, for international oncology patients, NGS is one of the most important tests before making a major treatment decision, especially if the patient has metastatic disease, rare cancer, disease progression after standard treatment, or incomplete previous biomarker testing.

 

 

 

Main Types of Immunotherapy

 

Immune Checkpoint Inhibitors

 

Checkpoint inhibitors are the most recognized type of cancer immunotherapy. They include drugs targeting PD-1, PD-L1, or CTLA-4. These treatments are used in many cancers and may be given alone or in combination with chemotherapy, targeted therapy, or another immunotherapy drug.

 

Examples include:

 

* Pembrolizumab

* Nivolumab

* Atezolizumab

* Durvalumab

* Cemiplimab

* Ipilimumab

* Avelumab

 

The correct drug depends on the cancer type, stage, biomarker results, previous treatments, and medical guidelines.

 

CAR-T Cell Therapy

 

CAR-T cell therapy is a personalized cellular therapy where a patient’s T cells are collected, genetically modified in a laboratory, and returned to the body to attack cancer cells. CAR-T therapy has changed treatment possibilities for some hematologic cancers, particularly certain leukemias, lymphomas, and multiple myeloma. In solid tumors, CAR-T remains more complex and is still developing compared with its established role in selected blood cancers.  

 

Monoclonal and Bispecific Antibodies

 

Some antibody-based therapies work by directly binding cancer cells or by bringing immune cells closer to cancer cells. Bispecific antibodies are designed to bind two targets at the same time, often connecting immune cells to tumor cells.

 

These treatments are particularly important in some hematologic cancers and are increasingly being studied in solid tumors.

 

Cancer Vaccines and Experimental Immunotherapies

 

Cancer vaccines are designed to train the immune system to recognize cancer-related antigens. Some are already used in specific settings, while many others are being studied in clinical trials. These approaches are promising but are not yet standard for every cancer type.

 

 

 

Immunotherapy Side Effects: What Patients Should Know

 

Immunotherapy is often perceived as easier than chemotherapy, and in some patients it may cause fewer classical chemotherapy-like side effects. However, immunotherapy can cause a different category of side effects called immune-related adverse events.

 

Because immunotherapy activates the immune system, the immune system can sometimes attack healthy tissues. According to ESMO patient guidance, immune-related side effects can affect almost any organ or tissue, most commonly the skin, colon, lungs, liver, and endocrine organs such as the thyroid or pituitary gland.  

 

Possible side effects include:

 

* Skin rash and itching

* Diarrhea or colitis

* Thyroid dysfunction

* Liver inflammation

* Lung inflammation, called pneumonitis

* Fatigue

* Joint pain

* Endocrine problems

* Kidney inflammation

* Neurological symptoms in rare cases

* Infusion reactions

 

Most immune-related side effects can be managed if detected early, but some can become serious. This is why immunotherapy should be given under medical oncology supervision, with proper monitoring before and during treatment.

 

Patients should immediately inform their oncology team if they experience new cough, shortness of breath, persistent diarrhea, severe fatigue, jaundice, severe headache, vision problems, fever, or unusual weakness.

 

 

 

When Should a Cancer Patient Consider Immunotherapy Abroad?

 

International patients often consider treatment abroad when they need access to advanced diagnostics, a second medical opinion, newer oncology drugs, or a more complete treatment strategy.

 

A patient may consider immunotherapy evaluation abroad if:

 

* The cancer is advanced or metastatic

* Standard treatment has stopped working

* Local biomarker testing is incomplete

* PD-L1, MSI, TMB, or NGS testing was not performed

* The patient needs a second opinion from an oncology team

* Treatment options are limited in the home country

* The patient wants access to multidisciplinary cancer care

* There is uncertainty between chemotherapy, targeted therapy, and immunotherapy

* The patient is searching for treatment in Turkey with medical travel support

 

For many patients from CIS countries, the Balkans, Germany, the United Kingdom, Canada, and the United States, Turkey can be a strong option because of experienced oncology specialists, modern hospitals, international patient coordination, and comparatively accessible treatment logistics.

 

 

 

Immunotherapy Treatment Planning in Turkey with RecMed Medical Travel

 

At RecMed Medical Travel, the goal is not simply to bring a patient to Turkey. The real goal is to help the patient receive a medically correct, realistic, and personalized treatment plan.

 

For cancer patients asking whether immunotherapy is suitable, RecMed can coordinate:

 

Medical Document Review

 

The patient’s medical records, pathology reports, imaging results, previous treatment history, and current condition are reviewed by the relevant medical team.

 

Oncology Second Opinion

 

A medical oncologist evaluates whether immunotherapy, chemotherapy, targeted therapy, surgery, radiation therapy, or a combined approach may be appropriate.

 

Biomarker and Molecular Testing Coordination

 

If previous testing is incomplete, additional tests may be recommended, including:

 

* PD-L1

* MSI/MMR

* TMB

* NGS tumor profiling

* HER2

* BRCA1/BRCA2

* EGFR, ALK, ROS1, BRAF, MET, RET, NTRK and other markers depending on cancer type

 

Personalized Treatment Plan

 

The treatment plan may include immunotherapy alone, immunotherapy plus chemotherapy, targeted therapy, radiation therapy, surgery, interventional oncology, or palliative supportive care depending on the patient’s condition.

 

International Patient Support

 

RecMed’s service structure includes support with hospital appointments, translation, transfers, accommodation guidance, and post-treatment follow-up coordination for international patients.  

 

 

 

Is Immunotherapy Better Than Chemotherapy?

 

Not always. Immunotherapy and chemotherapy work differently.

 

Chemotherapy directly attacks rapidly dividing cells, including cancer cells. Immunotherapy helps the immune system recognize and attack cancer cells. In some cancers, immunotherapy can produce long-lasting responses, but in other cases chemotherapy, targeted therapy, or a combined treatment may be more effective.

 

For example:

 

* Some lung cancer patients may receive immunotherapy alone if PD-L1 is very high and there are no driver mutations.

* Some patients may need chemotherapy plus immunotherapy.

* Some patients with EGFR or ALK-positive lung cancer may benefit more from targeted therapy first.

* MSI-H colorectal cancer may respond strongly to immunotherapy.

* Microsatellite-stable colorectal cancer usually does not respond well to checkpoint inhibitor monotherapy.

 

This is why treatment should not be selected based only on the drug name. It should be selected based on the patient’s full medical profile.

 

 

 

Can Stage 4 Cancer Be Treated With Immunotherapy?

 

Yes, in selected patients. Many immunotherapy indications are for advanced, unresectable, recurrent, or metastatic cancers. However, stage 4 disease does not automatically mean immunotherapy will work.

 

The decision depends on:

 

* Cancer type

* Biomarker results

* Previous treatments

* Speed of disease progression

* Metastatic sites

* Symptoms

* General health

* Organ function

* Availability of approved drugs or clinical trials

 

Some stage 4 patients may have meaningful disease control with immunotherapy. Others may need chemotherapy, targeted therapy, radiation, surgery for symptom control, or best supportive care. The correct decision requires individualized oncology assessment.

 

 

 

Who May Not Be a Good Candidate for Immunotherapy?

 

Immunotherapy may not be suitable or may require extra caution in patients with:

 

* Active autoimmune disease

* Previous organ transplant

* Severe uncontrolled infection

* Poor organ function

* Severe lung disease

* Rapidly progressive disease needing immediate tumor reduction

* Poor performance status

* History of severe immune-related toxicity

* Certain genetic driver mutations where targeted therapy is preferred first

 

This does not always mean immunotherapy is impossible, but it means the risk-benefit balance must be carefully evaluated by an oncologist.

 

 

 

Frequently Asked Questions

 

Can immunotherapy cure cancer?

 

In some patients, immunotherapy can produce long-term remission or durable disease control. However, it is not a guaranteed cure. The chance of success depends on cancer type, biomarkers, disease stage, previous treatments, and the patient’s immune response.

 

How do I know if Keytruda or Opdivo is suitable for me?

 

Suitability depends on diagnosis, stage, previous treatment, PD-L1 level, MSI/MMR status, TMB, NGS results, and medical guidelines. A medical oncologist should evaluate the full case before recommending pembrolizumab, nivolumab, or any other immunotherapy drug.

 

What is the most important test before immunotherapy?

 

There is no single test for every patient. PD-L1, MSI/MMR, TMB, and NGS may all be important depending on the cancer type. For advanced cancer patients, comprehensive molecular profiling is often very valuable.

 

Can immunotherapy be combined with chemotherapy?

 

Yes. In several cancers, immunotherapy is combined with chemotherapy to improve response rates. This is common in some lung cancers, gastric cancers, triple-negative breast cancer, and other tumors depending on the clinical situation.

 

How long does immunotherapy treatment last?

 

Treatment duration depends on cancer type, response, side effects, and treatment protocol. Some patients receive immunotherapy for months, while others may continue for up to two years or longer depending on the indication and medical judgment.

 

What happens if immunotherapy does not work?

 

If cancer progresses despite immunotherapy, the oncology team may consider chemotherapy, targeted therapy, radiation therapy, clinical trials, local treatments for metastases, or supportive care depending on the case.

 

 

 

Why Choose RecMed for Immunotherapy Evaluation in Turkey?

 

Choosing immunotherapy is a serious medical decision. It should be based on science, not hope alone. The most responsible approach is to review the diagnosis, confirm the pathology, perform the necessary biomarker testing, and create a personalized treatment plan.

 

RecMed Medical Travel supports international patients by coordinating:

 

* Oncology second opinions

* Advanced diagnostics

* Biomarker and molecular testing

* Hospital appointments in Turkey

* Translation and patient communication

* Transfer and accommodation guidance

* Treatment planning and follow-up coordination

 

For patients from the CIS region, Balkans, Europe, USA, and Canada, RecMed provides a structured pathway to understand whether immunotherapy is truly appropriate and what treatment options may be available in Turkey.

 

 

 

Conclusion

 

Immunotherapy has become one of the most important advances in cancer treatment. For selected patients, it may offer meaningful tumor control, longer survival, and in some cases durable remission. But immunotherapy is not suitable for every patient, and it should never be started without proper medical evaluation.

 

The most important step is correct patient selection. This usually requires pathology review, PD-L1 testing, MSI/MMR testing, TMB evaluation, NGS tumor profiling, and a complete oncology assessment.

 

At RecMed Medical Travel, we help international cancer patients access advanced oncology evaluation and personalized treatment planning in Turkey. If you or your loved one has been diagnosed with cancer and wants to understand whether immunotherapy may be an option, our team can help organize the next steps clearly, safely, and professionally.

 

 

 

References

1. National Cancer Institute. Immune Checkpoint Inhibitors. Cancer.gov. Updated April 7, 2022.
2. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clinical Cancer Research. 2019.
3. U.S. Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. June 17, 2020.
4. Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clinical Cancer Research. 2021.
5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2016.
6. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018.
7. André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. New England Journal of Medicine. 2020.
8. U.S. Food and Drug Administration. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer. June 29, 2020.
9. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2024.
10. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022.
11. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021.
12. Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology. 2022.